Supplementary Figure 6 from Identification of Mir-133B and RB1CC1 As Independent Predictors for Biochemical Recurrence and Potential Therapeutic Targets for Prostate Cancer

Xia Li,Xuechao Wan,Hongbing Chen,Shu Yang,Yiyang Liu,Wenjuan Mo,Delong Meng,Wenting Du,Yan Huang,Hai Wu,Jingqiang Wang,Tao Li,Yao Li

DOI: https://doi.org/10.1158/1078-0432.22450098.v1

2023-01-01

Abstract:PDF file - 229KB, RB1CC1 affected cell cycle and apoptosis in LNCaP cells.

What problem does this paper attempt to address?

Supplementary Figure 4 from Identification of Mir-133B and RB1CC1 As Independent Predictors for Biochemical Recurrence and Potential Therapeutic Targets for Prostate Cancer

Delong Meng

DOI: https://doi.org/10.1158/1078-0432.22450104.v1

2023-01-01

Abstract:PDF file - 458KB, Quantitative analyses of activated caspase and caspase-3 in LNCaP and PC-3 cells and the transfection efficiency in these two cell lines.
Data from Identification of Mir-133B and RB1CC1 As Independent Predictors for Biochemical Recurrence and Potential Therapeutic Targets for Prostate Cancer

Xia Li,Xuechao Wan,Hongbing Chen,Shu Yang,Yiyang Liu,Wenjuan Mo,Delong Meng,Wenting Du,Yan Huang,Hai Wu,Jingqiang Wang,Tao Li,Yao Li

DOI: https://doi.org/10.1158/1078-0432.ccr-13-1588

2014-01-01

Abstract:Abstract Objective: We aimed to investigate the contribution of microRNA-133b (miR-133b) in prostate cancer cell proliferation, cell cycle, and apoptosis. We also examined expression of miR-133b in prostate cancer tissues, and evaluated the prognostic significance of miR-133b, as well as its target gene RB1CC1 in patients with prostate cancer after radical prostatectomy. Experimental Design: miR-133b mimics (miR-133bm) and anti–miR-133b were transfected into LNCaP and PC-3 cells. CCK-8 was used to look at cell proliferation, flow cytometric analysis was carried out to study cell cycle, and apoptosis was determined by caspase-3 activity. miR-133b expression was assessed by real-time reverse transcription PCR and in situ hybridization in prostatic cell lines and 178 prostate tissue samples, respectively. The protein level of RB1CC1 was examined by Western blot and immunohistochemistry in prostatic cell lines and prostate tissue samples, respectively. Results: Overexpression of miR-133b in LNCaP cells boosted cell proliferation and cell-cycle progression, but inhibited apoptosis; in contrast, miR-133bm promoted cell apoptosis, but suppressed cell proliferation and cell-cycle progression in PC-3 cells. In LNCaP cells, silencing of RB1CC1, a target of miR-133b, inhibited cell apoptosis, and promoted cell-cycle progression. Moreover, miR-133b expression was significantly inversely correlated with RB1CC1 expression in prostate cancer tissues. Multivariate Cox analysis indicated that miR-133b and RB1CC1 might be two independent prognostic factors of biochemical recurrence. Conclusions: miR-133b might enhance tumor-promoting properties in less aggressive LNCaP cells, whereas this miR may act as a tumor suppressor in more aggressive PC-3 cells. miR-133b and RB1CC1 were independent prognostic indicators for prostate cancer. Clin Cancer Res; 20(9); 2312–25. ©2014 AACR.
Supplementary Materials and Methods, Figure Legends, Tables 1 - 9 from Identification of Mir-133B and RB1CC1 As Independent Predictors for Biochemical Recurrence and Potential Therapeutic Targets for Prostate Cancer

Xia Li,Xuechao Wan,Hongbing Chen,Shu Yang,Yiyang Liu,Wenjuan Mo,Delong Meng,Wenting Du,Yan Huang,Hai Wu,Jingqiang Wang,Tao Li,Yao Li

DOI: https://doi.org/10.1158/1078-0432.22450095.v1

2023-01-01

Abstract:PDF file - 183KB, Table S1. Correlation between miR-133b expression and RB1CC1 protein level and clinicopathologic features in prostate cancer patients after radical prostatectomy (RP). Table S2. 5-year biochemical recurrence (BCR)-free survival rates and mean BCR-free time for negative and positive miR-133b expression (a) and RB1CC1 expression (b) groups of prostate cancer patients after RP. Table S3. Sequences of synthetic oligonucleotides. Table S4. Primers used for real-time PCR amplification. Table S5. Locations and primer pairs for candidate AREs of miR-133b and negative control (a region of the DNA adjacent to miR-133b gene without a putative ARE). Table S6. Primers used for positive and negative DNA controls of ChIP assay. Table S7. Primers used for cloning the wild-type and mutation of 3'-UTR of RB1CC1 gene into pGL3-promoter Luciferase vector downstream of the Luciferase gene. Table S8. Pearson's rank correlation coefficient analysis. Table S9. Spearman's rank correlation coefficient analysis.
Nonconserved Mir‐608 Suppresses Prostate Cancer Progression Through RAC2/PAK4/LIMK1 and BCL2L1/caspase‐3 Pathways by Targeting the 3′‐utrs of RAC2/BCL2L1 and the Coding Region of PAK4

Xu Zhang,Jiajie Fang,Shiming Chen,Weiyu Wang,Shuai Meng,Ben Liu

DOI: https://doi.org/10.1002/cam4.2455

2019-01-01

Abstract:The aim of this study is to investigate the functions and mechanisms of miR-608 in prostate cancer (PCa). CISH and qRT-PCR analysis demonstrated that miR-608 was low expressed in PCa tissues and cells, which was partly attributed to the methylation of CpG island adjacent to the transcription start site (TSS) of miR-608 gene. Intracellular miR-608 overexpression inhibited in vivo PCa tumor growth, and suppressed PCa cell proliferation, G2/M transition, and migration in vitro, which was independent of EMT-associated mechanisms. Then RAC2, a GTPase previously deemed hematopoiesis-specific but now discovered to exist and play important roles in PCa, was verified by western blot and dual-luciferase reporter assays to mediate the effects of miR-608 through RAC2/PAK4/LIMK1/cofilin pathway. MiR-608 also promoted the apoptosis of PCa cells through BCL2L1/caspase-3 pathway by targeting the 3'-UTR of BCL2L1. Moreover, PAK4, the downstream effector of RAC2, was found to be targeted by miR-608 at the mRNA coding sequence (CDS) instead of the canonical 3'-UTR. Knocking down RAC2, PAK4, or BCL2L1 with siRNAs reproduced the antiproliferative, mitosis-obstructive, antimigratory and proapoptotic effects of miR-608 in PCa cells, which could be attenuated by downregulating miR-608. In conclusion, miR-608 suppresses PCa progression, and its activation provides a new therapeutic option for PCa.
Fifteen-MiRNA-Based Signature is a Reliable Prognosis-Predicting Tool for Prostate Cancer Patients.

Zichen Bian,Xinbo Huang,Yiding Chen,Jialin Meng,Xingliang Feng,Meng Zhang,Li Zhang,Jun Zhou,Chaozhao Liang

DOI: https://doi.org/10.7150/ijms.49412

2021-01-01

International Journal of Medical Sciences

Abstract:Recurrence is a major problem for prostate cancer patients, thus, identifying prognosis-related markers to evaluate clinical outcomes is essential. Here, we established a fifteen-miRNA-based recurrence-free survival (RFS) predicting signature based on the miRNA expression profile extracted from The Cancer Genome Atlas (TCGA) database by the LASSO Cox regression analysis. The median risk score generated by the signature in both the TCGA training and the external Memorial Sloan-Kettering Cancer Center (MSKCC) validation cohorts was employed and the patients were subclassified into low- and high-risk subgroups. The Kaplan-Meier plot and log-rank analyses showed significant survival differences between low- and high-risk subgroups of patients (TCGA, log-rank P < 0.001 & MSKCC, log-rank P = 0.045). In addition, the receiver operating characteristic curves of both the training and external validation cohorts indicated the good performance of our model. After predicting the downstream genes of these miRNAs, the miRNA-mRNA network was visualized by Cytoscape software. In addition, pathway analyses found that the differences between two groups were mainly enriched on tumor progression and drug resistance-related pathways. Multivariate analyses revealed that the miRNA signature is an independent indicator of RFS prognosis for prostate cancer patients with or without clinicopathological features. In summary, our novel fifteen-miRNA-based prediction signature is a reliable method to evaluate the prognosis of prostate cancer patients.
Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133<sup>+</sup> Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Lixing Zhang,Hefen Sun,Fangyu Zhao,Peixiang Lu,Ge Chen,Hong Li,Helei Hou,Mingxia Yan,Taoyang Chen,Guoping Jiang,Haiyang Xie,Ying Cui,Xiaowu Huang,Jia Fan,Ming Yao,Jinjun Li

DOI: https://doi.org/10.1158/0008-5472.22395141

2023-01-01

Abstract:PDF file - 47K, Sequences of primers used in this study
Supplementary Table 1 from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Lixing Zhang,Hefen Sun,Fangyu Zhao,Ping Lu,Chao Ge,Hong Li,Helei Hou,Mingxia Yan,Taoyang Chen,Guoping Jiang,Haiyang Xie,Ying Cui,Xiaowu Huang,Jia Fan,Ming Yao,Jinjun Li

DOI: https://doi.org/10.1158/0008-5472.22395144.v1

2023-01-01

Abstract:PDF file - 82K, Antibodies used in this study
Supplementary Figures 1-3, Tables 1-3, Table 7, Legends for Figures 1-3, Tables 1-7 from B-Raf Activation Cooperates with PTEN Loss to Drive C-Myc Expression in Advanced Prostate Cancer

Jingqiang Wang,Takashi Kobayashi,Nicolas Floc'h,Carolyn Waugh Kinkade,Alvaro Aytes,David Dankort,Celine Lefebvre,Antonina Mitrofanova,Robert D. Cardiff,Martin McMahon,Andrea Califano,Michael M. Shen,Cory Abate-Shen

DOI: https://doi.org/10.1158/0008-5472.22394105

2023-01-01

Abstract:PDF file - 404K, Supplementary Figure 1: Strategy for inducible recombination in the prostate. Supplementary Figure 2: Analyses of tumor regression following castration. Supplementary Figure 3: Gene Set Enrichment Analysis (GSEA). Supplementary Table 1: List of the primers used in this study. Supplementary Table 2: List of antibodies for used in this study. Supplementary Table 3: Summary of phenotypic analyses. Supplementary Table 7: Summary of preclinical data
Supplementary Figure 1 from DNA Methylation-Mediated Repression of Mir-886-3p Predicts Poor Outcome of Human Small Cell Lung Cancer

Jianzhong Cao,Yongmei Song,Nan Bi,Jie Shen,Wenyang Liu,Jing Fan,Guogui Sun,Tong,Jie He,Yuankai Shi,Xun Zhang,Ning Lu,Yinghua He,Hongyu Zhang,Kelong Ma,Xiaoying Luo,Lei Lv,Hui Deng,Jing Cheng,Jingde Zhu,Luhua Wang,Qimin Zhan

DOI: https://doi.org/10.1158/0008-5472.22397222

2023-01-01

Abstract:PDF file - 129K, Kaplan-Meier analyses for progression free survival (PFS) and distant metastasis free survival (DMFS) between the low and high miR-886-3p expressing groups.
An Integrated Bioinformatics Analysis to Investigate the Targets of Mir-133A-1 in Breast Cancer

Yanchun Meng,Hao Tang,Zhiguo Luo,Wenlong Tan,Lin Chen,Yiqun Du,Zhonghua Tao,Mingzhu Huang,Wenhua Li,Jun Cao,Leiping Wang,Ting Li,Xin Liu,Fangfang Lv,Xiaojian Liu,Jian Zhang,Lei Zheng,Xichun Hu

DOI: https://doi.org/10.21037/tcr-20-2681

2021-01-01

Translational Cancer Research

Abstract:BACKGROUND:The microRNA (miRNA) miR-133a-1 has been identified as a tumor suppressor in breast cancer. However, the underlying mechanisms of miR-133a-1 in breast cancer have not been fully elucidated. This study aimed to explore the targets of miR-133a-1 in breast cancer using an integrated bioinformatics approach.METHODS:Human SKBR3 breast cancer cells were transfected with miR-133a-1 or a miRNA negative control (miRNA-NC) for 48 hours. The RNA-seq sequencing technique was performed to identify the differential expression of genes induced by miR-133a-1 overexpression. Functional enrichment analysis was conducted to determine the target genes and pathways involved in breast cancer.RESULTS:Breast cancer patients with high levels of miR-133a-1 expression commonly showed longer overall survival compared to patients with a low level of miR-133a-1 expression. Using Cuffdiff, we identified 1,216 differentially expressed genes induced by miR-133a-1 overexpression, including 653 upregulated and 563 downregulated genes. MOCS3 was the most upregulated gene and KRT14 was the most downregulated gene. The top 10 pathways related to the differentially expressed genes were identified through Gene Ontology (GO) enrichment analysis. Sex-determining region Y-box 9 (SOX9) demonstrated the highest semantic similarities among the differentially expressed genes. Since SOX9 and CD44 were hub nodes in the protein-protein interaction network, the SOX9 gene may be a target of miR-133a-1 in breast cancer.CONCLUSIONS:This report provides useful insights for understanding the underlying mechanisms in the pathogenesis of breast cancer.
Supplementary Figure 4 from DNA Methylation-Mediated Repression of Mir-886-3p Predicts Poor Outcome of Human Small Cell Lung Cancer

Jianzhong Cao,Yongmei Song,Nan Bi,Jie Shen,Wenyang Liu,Jing Fan,Guogui Sun,Tong,Jie He,Yuankai Shi,Xun Zhang,Ning Lu,Yinghua He,Hongyu Zhang,Kelong Ma,Xiaoying Luo,Lei Lv,Hui Deng,Jing Cheng,Jingde Zhu,Luhua Wang,Qimin Zhan

DOI: https://doi.org/10.1158/0008-5472.22397213.v1

2023-01-01

Abstract:PDF file - 152K, Forced expression of PLK1 and TGF-β1 reversed the phenotype created by Mimic transfection in NCI-H446 cells.
Supplementary Figure A1 from Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer

Ke‐Da Yu,Rui Zhu,Mei Zhan,Angel Rodriguez,Wei Yang,Stephen T.C. Wong,Andreas Makris,Brian D. Lehmann,Xi Chen,Ingrid A. Mayer,Jennifer A. Pietenpol,Zhi‐Ming Shao,W. Fraser Symmans,Jenny Chang‐Claude

DOI: https://doi.org/10.1158/1078-0432.22446909

2023-01-01

Abstract:Supplementary Figure A1 PDF file 73K, Subgroup analysis of the extended validation cohort
Identification of Mir-130B As an Oncogene in Renal Cell Carcinoma

Yifan Li,Duqun Chen,Yuchi Li,Lu Jin,Jiaju Liu,Zhengmeng Su,Zhengyu Qi,Min Shi,Zhimao Jiang,Yaoting Gui,Shangqi Yang,Xiangming Mao,Yongqing Lai

DOI: https://doi.org/10.3892/mmr.2015.4744

IF: 3.423

2015-01-01

Molecular Medicine Reports

Abstract:Renal cell carcinoma (RCC) is the most common type of renal tumor, which has a poor prognosis. Improvements in understanding the underlying molecular biology of RCC has led to systemic treatments, which have markedly improved patient outcomes. Therefore, it is necessary and worthwhile to identify novel biomarkers for RCC. MicroRNAs (miRNAs) have been found to be important in a wide range of biological and pathological processes, including cell differentiation, migration, growth, proliferation, apoptosis and metabolism. Aberrant expression of miRNA‑130b has previously been reported in tumors, however, its role in RCC remains to be elucidated. In the present study, the upregulation of miR‑130b was observed in RCC tissues and cell lines using reverse transcription‑quantitative polymerase chain reaction analysis, which was consistent with previous microRNA profiling in RCC. Furthermore, the effects of miR‑130b on cell migration, proliferation and apoptosis were examined using a wound scratch assay, an MTT assay and flow cytometric analysis, respectively. The results demonstrated that the downregulation of miR‑130b by a synthesized inhibitor inhibited cell migration, suppressed cell proliferation and induced RCC cell apoptosis. The present study was the first, to the best of our knowledge, to suggest that miR‑130b may be a promising biomarker for diagnosis and a therapeutic target for the treatment of RCC. Further investigations are required to examine the roles and target genes of miR‑130b in RCC.
Identification of miRNA signature in cancer-associated fibroblast to predict recurrent prostate cancer

Wenbo Xu,Shuai Liu,Longtu Ma,Long Cheng,Qingchao Li,Liangliang Qing,Yongjin Yang,Zhilong Dong

DOI: https://doi.org/10.1016/j.compbiomed.2024.108989

Abstract:Background: Cancer-associated fibroblasts (CAFs) are one of the major components of prostate stromal cells, which play a crucial part in tumor development and treatment resistance. This study aimed to establish a model of CAFs-related microRNAs (miRNAs) to assess prognostic differences, tumor microenvironments, and screening of anticancer drugs by integrating data from single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing (buRNA-seq). Methods: scRNA-seq and buRNA-seq data of primary prostate cancer (PCa) were downloaded from Gene Expression Omnibus and The Cancer Genome Atlas databases. Statistical methods including Least absolute shrinkage and selection operator (Lasso), Lasso penalized, Random Forest, Random Forest Combination, and Support Vector Machine (SVM) were performed to select hub miRNAs. Pathway analyses and assessment of infiltrating immune cells were conducted using Gene Set Enrichment Analysis and the CIBERSORT algorithm. The expression of CAFs-related miRNAs in fibroblast cell lines were validated through quantitative real-time PCR. Cell Counting Kit 8 (CCK8), wound-healing, clone formation, and cell migration assays were used to explore cell proliferation, growth, and migration in vitro. A mouse xenograft model was established to investigate the effect of CAFs on tumor growth in vivo. Results: Through single-cell transcriptomics analysis in 34 PCa patients, 89 CAFs-related mRNAs were identified. A prognostic model based on 9 CAFs-related miRNAs (hsa-miR-1258, hsa-miR-133b, hsa-miR-222-3p, hsa-miR-145-3p, hsa-miR-493-5p, hsa-miR-96-5p, hsa-miR-15b-5p, hsa-miR-106b-5p, and hsa-miR-191-5p) was established to predict biochemical recurrence (BCR). We have determined through two prediction methods that NVP-TAE684 may be the optimal targeted therapy drug for treating CAFs. Downregulation of hsa-miR-106b-5p in CAFs significantly suppressed cell proliferation, migration, and colony formation in vitro. In vivo studies using a xenograft model further confirmed that hsa-miR-106b-5p downregulation significantly reduced tumor growth. Conclusion: Our findings conducted an integrated bioinformatic analysis to develop a CAFs-related miRNAs model that provides prognostic insights into individualized and precise treatment for prostate adenocarcinoma patients. Downregulation of miR-106b-5p in CAFs significantly suppressed tumor growth, suggesting a potential therapeutic target for cancer treatment.
Supplementary Figure 4 from Primate-Specific Mir-663 Functions As a Tumor Suppressor by Targeting <i>pik3cd</i> and Predicts the Prognosis of Human Glioblastoma

Shuang Yu,Cong Chen,Xia Zhang,Qing Liu,Jun Xu,Huarong Zhang,Xin Yao,Tao Jiang,Zhicheng He,Yang Ren,Wei Cui,Cheng Xu,Линг Лиу,You‐Hong Cui,Shizhu Yu,Yi‐Fang Ping,Xiu‐Wu Bian

DOI: https://doi.org/10.1158/1078-0432.22452560

2023-01-01

Abstract:PDF file - 1654K, Supplementary Fig. S4. The suppressive effects of miR-663 on PIK3CD and its downstream proliferation and invasion-related targets.
Supplementary Figure 2 from Chimeric Transcript Generated by Cis-Splicing of Adjacent Genes Regulates Prostate Cancer Cell Proliferation

Yanmei Zhang,Mei Gong,Huiling Yuan,Hong G. Park,Henry F. Frierson,Hui Li

DOI: https://doi.org/10.1158/2159-8290.22528769

2023-01-01

Abstract:PDF file - 175K, Androgen effect on SLC45A3-ELK4 in LNCaP cells
Supplementary Figure 5 from DNA Methylation-Mediated Repression of Mir-886-3p Predicts Poor Outcome of Human Small Cell Lung Cancer

Jianzhong Cao,Yongmei Song,Nan Bi,Jie Shen,Wenyang Liu,Jing Fan,Guogui Sun,Tong,Jie He,Yuankai Shi,Xun Zhang,Ning Lu,Yinghua He,Hongyu Zhang,Kelong Ma,Xiaoying Luo,Lei Lv,Hui Deng,Jing Cheng,Jingde Zhu,Luhua Wang,Qimin Zhan

DOI: https://doi.org/10.1158/0008-5472.22397210

2023-01-01

Abstract:PDF file - 98K, The PLK1 protein levels in FFEF specimens in miR-886-3p high and low expression groups of SCLC samples (13 each).
RB1 aberrations predict outcomes of immune checkpoint inhibitor combination therapy in NSCLC

Qian Wang,Tao Yu,Zi-Hao Ke,Fu-Feng Wang,Jia-Ni Yin,Yang Shao,Kai-Hua Lu

DOI: https://doi.org/10.3389/fonc.2023.1172728

IF: 4.7

2023-06-27

Frontiers in Oncology

Abstract:Introduction: Immune checkpoint inhibitors (ICI) have changed the treatment of non-small cell lung cancer (NSCLC). Furthermore, compared with monotherapy, ICI combination therapy had better efficacy and partly different mechanism. Therefore, we aim to investigate and improve biomarkers specialized for ICI combination therapy. Methods: We enrolled 53 NSCLC patients treated with ICI combination therapy and collected their tissue and plasma samples to perform next-generation sequencing (NGS) with a 425-gene panel. Results: The line of treatment was the only clinical factor significantly affecting objective response rate (ORR) and progression-free survival (PFS). Surprisingly, classical markers PD-L1 and TMB only had limited predictive values in the ICI combination therapy. Instead, we found RB1 mutation was significantly associated with prognosis. Patients with mutated RB1 had shorter PFS than those with wild RB1 (134d vs 219d, p=0.018). Subsequent analysis showed the RB1 related mutated cell cycle and chromosomal instability were also deleterious to prognosis (103d vs 411d, p<0.001; 138d vs 505d, p=0.018). Additionally, patients with more circulating tumor DNA (ctDNA) had significantly shorter PFS (41d vs 194d, p=0.0043). Conclusion: This study identified that NSCLC patients with mutated RB1 were less sensitive to ICI combination therapy. RB1 mutations and following cell cycle abnormalities and chromosomal instability can potentially guide clinical management.

oncology
Supplementary Figures S1-S6 from Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ Inhibitor BAY1082439

Yongkang Zou,Zhi Qi,Weilong Guo,Liuzhen Zhang,Marcus Ruscetti,Tanu Shenoy,Ningshu Liu,Hong Wu

DOI: https://doi.org/10.1158/1535-7163.22504362

2023-01-01

Abstract:Figure S1. Effects of BAY1082439 on cell apoptosis and cell cycle; Figure S2. BAY1082439 is well tolerated in vivo; Figure S3. BAY1082439 treatment impedes prostate tumor invasion; Figure S4. BAY1082439 treatment inhibit CRPC growth in castrated CP mice; Figure S5. B cell infiltration promote CRPC growth in CP model; Figure S6. Effects of BAY1082439 on splenic B cell growth and tumor infiltrating CD8 T cell
Supplemental Table 1 and Figure 1 from FOXP3–miR-146–NF-κB Axis and Therapy for Precancerous Lesions in Prostate

Runhua Liu,Bin Yi,Wei Shi,Wei‐Hsiung Yang,Karen Hart,Priyanka Chauhan,Wei Zhang,Xiaoyu Mao,Xiuping Liu,Chang-Gong Liu,Lizhong Wang

DOI: https://doi.org/10.1158/0008-5472.22407933.v1

2023-01-01

Abstract:Supplemental Table 1: Primer sequences used in this study. Supplemental Figure 1: The effect of FOXP3, NF-κB p65-siRNA, and NF-κB inhibitor bortezomib on the growth of DU145 cells.

Supplementary Figure 6 from Identification of Mir-133B and RB1CC1 As Independent Predictors for Biochemical Recurrence and Potential Therapeutic Targets for Prostate Cancer

Supplementary Figure 4 from Identification of Mir-133B and RB1CC1 As Independent Predictors for Biochemical Recurrence and Potential Therapeutic Targets for Prostate Cancer

Data from Identification of Mir-133B and RB1CC1 As Independent Predictors for Biochemical Recurrence and Potential Therapeutic Targets for Prostate Cancer

Supplementary Materials and Methods, Figure Legends, Tables 1 - 9 from Identification of Mir-133B and RB1CC1 As Independent Predictors for Biochemical Recurrence and Potential Therapeutic Targets for Prostate Cancer

Nonconserved Mir‐608 Suppresses Prostate Cancer Progression Through RAC2/PAK4/LIMK1 and BCL2L1/caspase‐3 Pathways by Targeting the 3′‐utrs of RAC2/BCL2L1 and the Coding Region of PAK4

Fifteen-MiRNA-Based Signature is a Reliable Prognosis-Predicting Tool for Prostate Cancer Patients.

Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133&lt;sup&gt;+&lt;/sup&gt; Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplementary Table 1 from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplementary Figures 1-3, Tables 1-3, Table 7, Legends for Figures 1-3, Tables 1-7 from B-Raf Activation Cooperates with PTEN Loss to Drive C-Myc Expression in Advanced Prostate Cancer

Supplementary Figure 1 from DNA Methylation-Mediated Repression of Mir-886-3p Predicts Poor Outcome of Human Small Cell Lung Cancer

An Integrated Bioinformatics Analysis to Investigate the Targets of Mir-133A-1 in Breast Cancer

Supplementary Figure 4 from DNA Methylation-Mediated Repression of Mir-886-3p Predicts Poor Outcome of Human Small Cell Lung Cancer

Supplementary Figure A1 from Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer

Identification of Mir-130B As an Oncogene in Renal Cell Carcinoma

Identification of miRNA signature in cancer-associated fibroblast to predict recurrent prostate cancer

Supplementary Figure 4 from Primate-Specific Mir-663 Functions As a Tumor Suppressor by Targeting &lt;i&gt;pik3cd&lt;/i&gt; and Predicts the Prognosis of Human Glioblastoma

Supplementary Figure 2 from Chimeric Transcript Generated by Cis-Splicing of Adjacent Genes Regulates Prostate Cancer Cell Proliferation

Supplementary Figure 5 from DNA Methylation-Mediated Repression of Mir-886-3p Predicts Poor Outcome of Human Small Cell Lung Cancer

RB1 aberrations predict outcomes of immune checkpoint inhibitor combination therapy in NSCLC

Supplementary Figures S1-S6 from Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ Inhibitor BAY1082439

Supplemental Table 1 and Figure 1 from FOXP3–miR-146–NF-κB Axis and Therapy for Precancerous Lesions in Prostate

Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133<sup>+</sup> Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplementary Figure 4 from Primate-Specific Mir-663 Functions As a Tumor Suppressor by Targeting <i>pik3cd</i> and Predicts the Prognosis of Human Glioblastoma